Study Evaluating Refacto For Pharmacovigilance

Wyeth

Status: Completed

Conditions: Hemophilia A

Treatments: Drug: Moroctocog alfa

Study type: Observational

Funder types: Industry

Identifiers

NCT00195442

3082A-100690

Details and patient eligibility

About

The purpose of this study is to investigate the effectiveness and safety of treatment with ReFacto under conditions of routine therapy. Furthermore a continuous benefit/risk assessment will be done.

Full description

Non-interventional study: subjects to be selected according to the usual clinical practice of their physician

Enrollment: 288 patients

Sex: Male

Volunteers: No Healthy Volunteers

Inclusion criteria

• Proven diagnosis of Hemophilia A

Exclusion criteria

• Contraindications according to Summary of Product Characteristics

Trial design

288 participants in 1 patient group

A

Description:

Patients with Hemophilia A

Treatment:

Drug: Moroctocog alfa